业内普遍认为作为华大智造布局北美的核心载体，CGI的剥离并非简单的资产处置，而是公司全球化战略的一次"换道"。 此前1月底华大智造曾披露2025年业绩预告，预计2025年归母净利润将亏损2.21亿元～2.73亿元，与2024年相比同比亏损将大幅收窄54.56%～ 63.22%，同期扣非净利润则为亏损3.2亿元～3.97亿元，同比亦收窄39.18%～50.67%。 而在最新公告中，华大智造表示，预计此次出售CGI获得的约5000万美元对价收入，将为其带来显著的直接收益和持续的现金流改善。 基因测序设备龙头华大智造的全球化战略迎来重大调整。在节前刚宣布拟3.66亿收购两家公司后，节后开工的第一天就又披露了一项出售 海外子公司的交易。 2月24日，公司公告披露，拟以5000万美元对价，将旗下美国全资子公司Complete Genomics（下称"CGI"）100%股权，转让给瑞士生物技术企 业Swiss Rockets。与此同时，双方进一步扩大合作边界，华大智造将其核心技术——光学测序仪StandardMPS在美国、加拿大地区的独占授 权，一并打包授予后者，同步配套给予该区域内相关通用测序技术的普通许可。 而值得注 ...

21世纪经济报道记者唐唯珂 基因测序设备龙头华大智造的全球化战略迎来重大调整。在节前刚宣布拟3.66亿收购两家公司后，节后 开工的第一天就又披露了一项出售海外子公司的交易。 2月24日，公司公告披露，拟以5000万美元对价，将旗下美国全资子公司Complete Genomics（下 称"CGI"）100%股权，转让给瑞士生物技术企业Swiss Rockets。与此同时，双方进一步扩大合作边界， 华大智造将其核心技术——光学测序仪StandardMPS在美国、加拿大地区的独占授权，一并打包授予后 者，同步配套给予该区域内相关通用测序技术的普通许可。 业内普遍认为作为华大智造布局北美的核心载体，CGI的剥离并非简单的资产处置，而是公司全球化战 略的一次"换道"。 此前1月底华大智造曾披露2025年业绩预告，预计2025年归母净利润将亏损2.21亿元～2.73亿元，与2024 年相比同比亏损将大幅收窄54.56%～63.22%，同期扣非净利润则为亏损3.2亿元～3.97亿元，同比亦收 窄39.18%～50.67%。 公开信息显示，CGI成立于2006年，2013年被华大集团收购，主要聚焦于基因测序技术研发与相关产品 ...

CGI原本是华大智造海外核心运营主体。 2月24日，国产基因测序仪龙头华大智造（688114.SH）盘中股价涨幅超过1%。 2025年前三季度，华大智造归属于上市公司股东的净利润仍亏损1.2亿元。 伴随着这次出售CGI公司，华大智造也在调整在北美市场的运营方式，不再是正面"死磕"，而是通过授 权模式间接参与北美市场。 2025年9月，华大智造方面曾将CoolMPS测序技术及通用测序技术的海外专利、技术秘密及商标的独占 许可授权给了SwissRockets。 这次交易，华大智造方面又增加将StandardMPS测序技术（以下简称"StandardMPS"）及通用测序技术有 偿授权给SwissRockets，授权区域为美国以及加拿大。 与此同时，本次交易也通过反向授权安排保障华大智造对CGI公司205项专利的永久使用权，确保全球 业务技术连贯性。 前一晚，华大智造公布了一项出售资产计划，拟将剥离相关资产及负债后的全资孙公司 CompleteGenomics,Inc.（下称"CGI"）100%股权出售给瑞士公司SwissRockets，出售价约5000万美元。 原本CGI归属于华大智造全资子公司MGIR&DHK旗下 ...

（华大智造公告） (编辑：杨燕 林辰) 近日，华大智造发布公告称，公司全资子公司MGIR&DHK与SwissRockets签署了《股份购买协议》， 拟以约5000万美元的对价出售剥离相关资产及负债后的全资子公司CompleteGenomics,Inc.（CGI）100% 股权。交易价格最终将依据交割情况确定。此外，公司与SwissRockets还签署了《授权许可协议修正 案》，新增将StandardMPS测序技术及通用测序技术有偿授权给SwissRockets。 此次交易预计将为公司带来显著的直接收益和持续的现金流改善，剥离CGI将减少归属于该业务单元的 亏损，从而提升公司整体盈利能力和经营效率。公司合计可获得不低于1.2亿美元的授权许可费，其中 包括已收到的2000万美元的首付款和未来的里程碑付款。交易后，公司将继续主导CoolMPS测序技术在 亚太及大中华区的业务拓展，并通过授权模式间接参与北美市场，优化全球资源配置。 ...

2月24日，深圳华大智造科技股份有限公司公告披露，出售子公司100%股权及调整 CoolMPS 测序技术 《授权许可协议》。 深圳华大智造科技股份有限公司（以下简称"华大智造"或"公司"）全资子公司 MGI Tech R&D HONG KONG CO., LIMITED（以下简称"MGI R&D HK"）与 Swiss Rockets AG（以下简称"Swiss Rockets"）签署了《股份购买协议》，拟将 MGI R&D HK 剥离相关资产 及负债后的全资子公司Complete Genomics, Inc.（以下简称"CGI"）100%股权以约 5,000 万美元的对价出 售给 Swiss Rockets，最终交易价格以交割情况为准。 MGIUS LLC、CGI 与 Swiss Rockets 签署了《授权许可协议修正案》，拟在《CoolMPS 授权许可协议》 基础上，新增将公司的 StandardMPS 测序技术（以下简称"StandardMPS"）及通用测序技术有偿授权给 Swiss Rockets。在美国及加拿大区域内，Swiss Rockets 将获得 StandardMPS 测序技术相关的专利、 ...

证券代码：688114 证券简称：华大智造 公告编号：2026-007 深圳华大智造科技股份有限公司 第二届董事会第二十次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 深圳华大智造科技股份有限公司（以下简称"公司"）第二届董事会第二十次会议于2026年2月14日以现 场结合通讯方式举行。会议通知已于2026年2月13日以邮件方式发出。全体董事一致同意豁免本次会议 的通知时限。会议应到董事10人，实到董事10人。公司董事长汪建先生因公务不便主持，与会董事一致 推举董事牟峰先生为本次会议的主持人。公司高级管理人员列席了董事会会议。本次董事会会议的召 集、召开程序符合《中华人民共和国公司法》《公司章程》等有关规定的要求。经与会董事审议和表 决，会议形成决议如下： 二、董事会会议审议情况 （一）审议通过《关于出售子公司100%股权及调整CoolMPS测序技术〈授权许可协议〉的议案》 公司全资子公司MGI Tech R&D HONG KONG CO., LIMITED（以下简称"MGI R&D H ...

Core Insights - The company reported a revenue of 1.869 billion yuan for the first three quarters of 2025, showing a slight year-on-year decrease of 0.01%, while the net loss attributable to shareholders was 120 million yuan, a reduction in loss of 74.2% year-on-year [1] - In Q3 2025, the company achieved a revenue of 755 million yuan, representing a year-on-year increase of 14.45%, with a net loss attributable to shareholders of 16 million yuan, a significant reduction in loss of 90.31% year-on-year [1] Revenue Structure and Cost Management - The company is optimizing its revenue structure and continuously promoting cost reduction and efficiency improvement, leading to gradual recovery in profits [2] - In the first three quarters of 2025, the revenue from the full-length sequencing business included 460 million yuan from instrument sales and 940 million yuan from reagent consumables, with the proportion of recurring revenue from reagents and services rising to nearly 70% [2] - The sales, management, and R&D expense ratios for Q3 2025 were 23.2%, 11.2%, and 14.8%, respectively, showing year-on-year decreases of 10.8, 12.2, and 12.7 percentage points, which contributed to the narrowing of losses [2] Market Share and Global Expansion - The company has significantly increased its market share domestically while continuing to expand in overseas markets, with a notable focus on technology export to support global layout [3] - In the first three quarters of 2025, the revenue from the sequencing business in China was 1 billion yuan, a year-on-year decrease of 5%, but the company secured over 70% of the bids for high-throughput sequencers, indicating a strong domestic market position [3] - The company reported revenues of 260 million yuan in the Europe and Africa region and 140 million yuan in the Americas, both showing a year-on-year increase of 14%, while the Asia-Pacific region saw a revenue of 110 million yuan, down 32% due to regional disruptions [3] - A recent licensing agreement with Swiss Rockets for sequencing technology is expected to generate an initial payment of 20 million USD and potential total revenues of at least 120 million USD, marking a new model for technology export [3] Profit Forecast - The company forecasts revenues of 3.585 billion, 4.184 billion, and 4.936 billion yuan for 2025-2027, with year-on-year growth rates of 19.01%, 16.69%, and 17.98% respectively [4] - The projected net profits attributable to shareholders for the same period are 29 million, 104 million, and 219 million yuan, with year-on-year growth rates of 104.79%, 262.33%, and 110.26% respectively [4]

Core Insights - Shenzhen BGI Genomics Co., Ltd. (referred to as "BGI") has entered into a technology licensing agreement with Swiss biotechnology company Swiss Rockets AG, marking a significant step in the international expansion of Chinese medical device companies [1][2] - The agreement involves the exclusive licensing of BGI's "CoolMPS" sequencing technology, which includes patents, trademarks, proprietary technology, and software for global development, production, and commercialization outside the Asia-Pacific and Greater China regions [1][2] Financial Aspects - BGI is set to receive a total of no less than $120 million in licensing fees, which includes a non-refundable upfront payment of $20 million, milestone payments of $20 million, and a tiered royalty percentage based on net sales of licensed products [1] Strategic Implications - This licensing agreement positions BGI as the first life science equipment company in China's medical device sector to expand internationally through patent licensing, setting a precedent for Chinese scientific instrument IP going global [2] - The arrangement allows BGI to retain operational rights in Greater China and the Asia-Pacific region, ensuring control over its core markets while leveraging the partnership to tap into potential global market growth [2]

Core Points - The company held its fourth extraordinary general meeting of shareholders on October 28, 2025, with no resolutions being rejected [2] - The meeting was conducted in compliance with the Company Law and the company's articles of association, with all necessary procedures followed [3][7] Group 1: Meeting Details - The meeting took place at the International Conference Center, Huada Space Center, Shenzhen [2] - A total of 416,516,155 shares were registered as of the meeting date, with 3,987,952 shares held in the company's repurchase account not entitled to vote [2] Group 2: Attendance - All 10 current directors and 3 current supervisors attended the meeting, along with the company secretary and senior management [4] Group 3: Voting and Resolutions - A key resolution regarding the signing of a licensing agreement for CoolMPS sequencing technology was approved [5] - The voting process included separate counting for minority investors, and related shareholders abstained from voting, totaling 583,800 shares [6] Group 4: Legal Verification - The meeting was witnessed by lawyers from JunHe (Shenzhen) Law Firm, who confirmed that all procedures and voting results were in accordance with legal requirements [7]

Core Insights - Shenzhen BGI Genomics Co., Ltd. has entered into a licensing agreement with Swiss biotechnology company SwissRocketsAG for the CoolMPS sequencing technology, marking a significant step in the internationalization of Chinese life science instruments [1][2] - The agreement will generate a minimum of $120 million in licensing fees for BGI, including a non-refundable upfront payment of $20 million and milestone payments of $20 million, along with a tiered royalty based on net sales of licensed products [1][2] Company Developments - BGI's third-quarter report for 2025 shows a revenue of 755 million yuan, a year-on-year increase of 14.45%, and a successful turnaround to profitability [2] - The company has established a global presence, covering over 110 countries and serving more than 3,560 users as of June 30, 2025 [2] - The collaboration with SwissRockets is expected to enhance BGI's international competitiveness and provide a sustainable global path for technology licensing and revenue sharing [2]